Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2024

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2024

DelveInsight’s, “Antisense Oligonucleotide Therapeutics – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Antisense Oligonucleotide Therapeutics Understanding

Antisense Oligonucleotide Therapeutics: Overview

Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms. By targeting the source of the pathogenesis, ASO-mediated therapies have an higher chance of success than therapies targeting downstream pathways. Advances in the understanding of ASO pharmacology have provided momentum for translating these therapeutics into the clinic. Two ASO-mediated therapies have received approval from the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Further advancement of ASOs in the clinic urgently requires optimization of ASO delivery, target engagement, and safety profile.

""Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Antisense Oligonucleotide Therapeutics pipeline landscape is provided which includes the disease overview and Antisense Oligonucleotide Therapeutics treatment guidelines. The assessment part of the report embraces, in depth Antisense Oligonucleotide Therapeutics commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Antisense Oligonucleotide Therapeutics collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Antisense Oligonucleotide Therapeutics R&D. The therapies under development are focused on novel approaches to treat/improve Antisense Oligonucleotide Therapeutics.

Antisense Oligonucleotide Therapeutics Emerging Drugs Chapters

This segment of the Antisense Oligonucleotide Therapeutics report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Antisense Oligonucleotide Therapeutics Emerging Drugs

• Cobitolimod: InDex Pharmaceuticals

Cobitolimod is part of InDex Pharmaceuticals’ DNA-based ImmunoModulatory Sequence (DIMS) platform. It is administered locally in the large intestine, where the substance binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells. The binding triggers the cells to product anti-inflammatory cytokines, agents that play an important role in reducing the inflammation and healing the wounds in the large intestine caused by UC. It is currently being evaluated in Phase III stage of development of Ulcerative colitis.

• Prexigebersen: Bio-Path Holdings

Prexigebersen (previously BP 100-1-01) is a neutral-charge, liposomal-delivered antisense cancer drug. It is designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2). Bio-Path is currently evaluating prexigebersen in Phase II program for the treatment of acute myeloid leukemia (AML). Prexigebersen has received orphan drug designation from the FDA and from the European Medicines Agency for AML.

Further product details are provided in the report……..

Antisense Oligonucleotide Therapeutics: Therapeutic Assessment

This segment of the report provides insights about the different Antisense Oligonucleotide Therapeutics drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Antisense Oligonucleotide Therapeutics

There are approx. 15+ key companies which are developing the therapies for Antisense Oligonucleotide Therapeutics. The companies which have their Antisense Oligonucleotide Therapeutics drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Antisense Oligonucleotide Therapeutics: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Antisense Oligonucleotide Therapeutics therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Antisense Oligonucleotide Therapeutics drugs.

Antisense Oligonucleotide Therapeutics Report Insights

• Antisense Oligonucleotide Therapeutics Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Antisense Oligonucleotide Therapeutics Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Antisense Oligonucleotide Therapeutics drugs?
• How many Antisense Oligonucleotide Therapeutics drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Antisense Oligonucleotide Therapeutics?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Antisense Oligonucleotide Therapeutics therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Antisense Oligonucleotide Therapeutics and their status?
• What are the key designations that have been granted to the emerging drugs?